Eva Domingo‐Domènech
Author
Alternate names E. Domenech, E. Domingo‐Doménech, E. Domingo‐Domènech, Eva Domingo Domenech, Eva Domingo Doménech +10 more
Past institutions Duran i Reynals Hospital, Institut Català d'Oncologia, Institut d'Investigació Biomédica de Bellvitge, Ajuntament de L’Hospitalet, Universitat de Barcelona +5 more
ORCID: Yes
H-index: 32
I10-index: 71
Works count: 208
Citations count: 4,143
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
2018 · Steven M. Horwitz, Owen A. O’Connor, et al. · The Lancet
Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients
2012 · Carlota Gudiol, Marta Bodro, et al. · Clinical Microbiology and Infection
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
2019 · Radhakrishnan Ramchandren, Eva Domingo‐Domènech, et al. · Journal of Clinical Oncology